Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study (Breast Cancer Research, (2017), 19, 1, (130), 10.1186/s13058-017-0920-8)

Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie HuntAmy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, Liewei Wang

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following publication of the original article [1], the authors would like to correct several typos in the article text: 1) Page 4-right panel, Line 10: “The take rate was 51.3% (21/39; 95% CI: 34.8-67.6%) in TN subtype;”. Take rate should be 20/39 not 21/39. Percentages are correct. 2) Page 4-right panel, Line 21: The last 2 sentences were corrected to be consistent with Table 2 as follows: “There was no take among the 18 luminal tumors. However, five of nine TN, and one of the eight HER2+ post-chemotherapy residual tumors took (verified breast tumor).” 3) Page 4-right panel, Table 2: Total implanted for Luminal B should be 14 instead of 18. The total number of implanted 35 was correct. 4) Page 5-left panel, Line 15: HER2+ tumors (7/17 vs. 2/15) should be (7/19 vs. 2/15). P-value is correct. 5) Page 5-left panel, Line 20, The number of luminal tumors should be 18 instead of 22. The authors sincerely apologize for any inconvenience.

Original languageEnglish (US)
Article number41
JournalBreast Cancer Research
Volume23
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study (Breast Cancer Research, (2017), 19, 1, (130), 10.1186/s13058-017-0920-8)'. Together they form a unique fingerprint.

Cite this